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Platelet reactivity during mild 
therapeutic hypothermia in patients  
with acute myocardial infarction treated 
with ticagrelor: study protocol  
of a single-centre study
ABSTRACT
In summary, the available data on the antiplatelet efficacy of P2Y12 receptor inhibitors suggest their less 
potent and/or delayed effect in patients undergoing mild therapeutic hypothermia (MTH). However, pre-
vious studies do not explain the mechanisms of the impact of MTH on platelet function. Moreover, there 
is a lack of evidence of any relationship between the increased prevalence of thrombotic complications 
in MTH patients and the anti-platelet effect of P2Y12 receptor inhibitors.
We hypothesise that MTH may interfere with the absorption of ticagrelor and consequently results in 
significant changes in the pharmacokinetic and pharmacodynamic profile of this P2Y12 receptor inhibitor. 
It cannot be ruled out that the high initial level of platelet activation in MTH patients may additionally modify 
the pharmacodynamics of ticagrelor. Malabsorption may slow down the desired antiplatelet effect, while 
high levels of platelet activation may reduce the antiplatelet effect of ticagrelor.
The aim of this study is to verify whether the use of MTH after resuscitation in out-of-hospital cardiac arrest 
(OHCA) patients with STEMI (ST-segment elevation myocardial infarction) treated with primary percuta-
neous coronary intervention (pPCI), affects the anti-platelet effect of ticagrelor. Moreover, we attempt to 
elucidate the mechanisms of impaired effect of ticagrelor in MTH patients based on pharmacodynamic 
and pharmacokinetic measurements.
To achieve the aim of the study, we planned the following: 1) comparison of the pharmacokinetic and 
pharmacodynamic results obtained from the study population (MTH + pPCI + ticagrelor) with results 
obtained from a demographically and clinically comparable population of patients with STEMI treated with 
primary PCI and receiving ticagrelor (pPCI + ticagrelor); and 2) analysis of the pharmacodynamic results 
in relation to the pharmacokinetic measurements in the target population.
Understanding the mechanisms standing behind the impact of MTH on the efficacy of platelet inhibition 
with P2Y12 inhibitors is pivotal in reducing the risk of thrombotic complications. The study is expected to 
provide information leading to improvement of the safety of MTH in STEMI patients with OHCA treated 
with pPCI and receiving ticagrelor. 
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Introduction
Platelet activation plays a key role in the pathophys-
iology of acute coronary syndromes, including myo-
cardial infarction with ST-segment elevation (STEMI). 
Pharmacological platelet inhibition with P2Y12 receptor 
antagonists and acetylsalicylic acid is essential for the 
treatment and prevention of thrombotic complications in 
patients with STEMI undergoing primary percutaneous 
coronary intervention (pPCI) [1–3].
The results of the PLATO study showed that treat-
ment with ticagrelor, a new potent inhibitor of the 
platelet P2Y12 receptor, reduces the overall mortality 
and cardiovascular thrombotic events, as compared 
with clopidogrel, in patients with acute coronary syn-
dromes (ACS), including STEMI [1]. The superiority of 
ticagrelor over clopidogrel in patients with ACS results 
from faster, more potent, and more uniform action of the 
former versus the latter of these drugs [1]. Ticagrelor 
currently holds a class I recommendation, level of evi-
dence B in patients with STEMI, both in the guidelines 
from the European Society of Cardiology (ESC) and 
from the American College of Cardiology/American 
Heart Association (ACCF/AHA) [2, 3].
Out-of-hospital cardiac arrest (OHCA) is the most 
frequent cause of sudden death in developed coun-
tries. OHCA survivors remaining in a coma despite 
restored cardiovascular function are saddled with a very 
high risk of death and serious neurological complica-
tions. The ESC and ACCF/AHA guidelines recommend 
the use of mild therapeutic hypothermia (MTH) in OHCA 
patients with myocardial infarction [2, 3]. According 
to the ESC guidelines [2], MTH is indicated early 
after resuscitation of cardiac arrest patients who are 
comatose or in deep sedation (Class of recommen-
dation I, level of evidence B). Immediate angiography 
with a view to pPCI is recommended in patients with 
resuscitated cardiac arrest, whose ECG shows STEMI 
(class of recommendation I, level of evidence B), and 
it should be also considered in survivors of cardiac 
arrest without diagnostic ECG ST-segment elevation, 
but with a high suspicion of ongoing infarction. (Class 
of recommendation IIa, level of evidence B) [2]. Ac-
cording to the ACCF/AHA guidelines [3], MTH should 
be started as soon as possible in comatose patients 
with STEMI and out-of-hospital cardiac arrest caused 
by ventricular fibrillation (VF) or pulseless ventricular 
tachycardia (VT), including patients who undergo pPCI 
(class of recommendation I, level of evidence B). Im-
mediate angiography and pPCI when indicated should 
be performed in resuscitated out-of-hospital cardiac 
arrest patients whose initial ECG shows STEMI (class 
of recommendation I, level of evidence B) [3].
Several studies, including our own [4, 5] as well as 
studies published by Casella et al. [6] and Dumas et 
al. [7], suggest that the combination of PCI and MTH is 
more effective than any of these methods used alone 
in the treatment of OHCA patients with ACS. However, 
there is a serious limitation of MTH in patients with acute 
myocardial infarction treated with PCI as described by 
Penela et al. [8]. They observed clinical resistance to 
clopidogrel with an extremely high incidence of acute 
stent thrombosis. In a small group of 11 MTH patients 
enrolled into the study, stent thrombosis occurred 
in five patients, while two other patients experienced 
other thrombotic complications [8]. This observation 
was not supported by any pharmacokinetic or pharma-
codynamic data that could explain the mechanisms of 
thrombotic complications. In another study, Ibrahim et 
al. [9] compared the antiplatelet effect of clopidogrel, 
prasugrel, and ticagrelor 24 hours after loading dose 
in patients treated with and without hypothermia. The 
authors found a significantly higher incidence of un-
responsiveness to the drug (PRI/VASP > 50%) only 
among those patients undergoing MTH who received 
clopidogrel (82% vs. 26%). However, the absolute 
values of PRI/VASP were also significantly higher in 
patients undergoing MTH and treated with ticagrelor. 
This study [9], suggesting less potent antiplatelet effect 
of all oral P2Y12 receptor inhibitors in patients under-
going MTH solely based on sparse pharmacodynamic 
data (one measurement after 24 hours), provides no 
information on pharmacokinetics, which would explain 
the mechanism of differences in platelet inhibition [9].
In summary, the available data on the antiplatelet 
efficacy of P2Y12 receptor inhibitors suggest their less 
potent and/or delayed effect in patients undergoing 
MTH. However, previous studies [8, 9] do not explain 
the mechanisms of impact of MTH on platelet function. 
Moreover, there is a lack of evidence of any relationship 
between the increased prevalence of thrombotic com-
plications in MTH patients and the anti-platelet effect of 
P2Y12 receptor inhibitors.
We hypothesise that MTH may interfere with the 
absorption of ticagrelor and consequently result in 
significant changes in the pharmacokinetic and phar-
macodynamic profile of this P2Y12 receptor inhibitor. 
It cannot be ruled out that the high initial level of platelet 
activation in MTH patients may additionally modify the 
pharmacodynamics of ticagrelor. Malabsorption may 
slow down the desired antiplatelet effect, while high 
levels of platelet activation may reduce the antiplatelet 
effect of ticagrelor.
The aim of this study is to verify whether the use 
of MTH after resuscitation in OHCA patients with 
STEMI treated with pPCI affects the anti-platelet effect 
of ticagrelor. Moreover, we attempt to elucidate the 
mechanisms of the impaired effect of ticagrelor in MTH 
patients based on the pharmacodynamic and pharma-
cokinetic measurements.
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Table 1. Inclusion criteria
INCLUSION CRITERIA
Study group Control group
Age > 18 years
Ecg findings suggestive of STEMI
Primary PCI with stenting of at least one coronary artery
Survival from OHCA
Sustained return of spontaneous circulation (ROSC) at least 20 minutes after the onset  
of resuscitation
Unconsciousness (glasgow coma scale score < 8 and > 3) after ROSC (in case of prior 
sedative drug administration assessed after reversal of their actions with naloxone/anexate)
Shockable initial rhythm
Age >18 years
ECG findings suggestive of stemi
Primary pci with stenting of at least 
one coronary artery
ECG — electrocardiography; STEMI — ST-segment elevation myocardial infarction; PCI — percutaneous coronary intervention; OHCA— out-of-
-hospital cardiac arrest
To achieve the aim of the study, we have planned 
the following:
 — comparison of the pharmacokinetic and pharmaco-
dynamic results obtained from the study population 
(MTH + pPCI + ticagrelor) with results obtained 
from a demographically and clinically comparable 
population of patients with STEMI treated with prima-
ry PCI and receiving ticagrelor (pPCI + ticagrelor);
 — analysis of the pharmacodynamic results in rela-
tion to the pharmacokinetic measurements in the 
target population.
Methods
This PK-PD, phase IV, single-centre, investigator-initi-
ated, prospective, observational study will be conducted 
in accordance with the Declaration of Helsinki and Good 
Clinical Practice guidelines. The protocol of the study was 
approved by the Ethics Committee of The Nicolaus Coper-
nicus University in Toruń, Collegium Medicum in Bydgo-
szcz (approval number KB 339/2015). Each patient with 
STEMI treated with pPCI without MTH will provide written, 
informed consent to participate in the study before enrol-
ment. In this group of patients, additional blood sampling 
is required in comparison to regular STEMI patients who 
do not participate in the study. In patients treated with ad-
ditional MTH due to OHCA it will not be possible to obtain 
informed consent before blood sampling; however, these 
patients will require no additional sampling outside the pro-
tocol of MTH monitoring. All patients before pPCI receive 
a loading dose of aspirin (300 mg) and a loading dose 
of ticagrelor (180 mg), according to the ESC guidelines.
Study population
Study group: 25 STEMI patients after OHCA aborted 
with successful resuscitation, treated with MTH, pPCI, 
and ticagrelor. 
Control group: 25 STEMI patients treated with pPCI 
and ticagrelor (both populations matched regarding the 
demographic and clinical variables).
Due to the lack of previous relevant studies, the 
number of patients that allows estimation of the final 
sample size sufficient to detect statistically significant 
differences in the primary endpoint was assumed ar-
bitrarily.
Based on a historical analysis of the number of 
OHCA patients with concomitant STEMI treated with 
pPCI, who underwent MTH therapy, the time required 
to enrol the assumed number of patients is estimated 
to be 20 months.
Inclusion criteria are shown in Table 1, and exclusion 
criteria are shown in Table 2.
Induction of hypothermia
The induction of hypothermia will start upon hospital 
admission, directly after the initial assessment of con-
sciousness [5], and will employ the following: 
 — ice packs — placed on the largest possible surface 
area of the patient’s body: neck, armpits, abdomen, 
groin, lower limbs;
 — infusion of cold fluid — 1–1.5 L of 4°C lactated 
Ringer’s solution or cold normal saline infused into 
the peripheral veins;
 — washing the patient’s skin with alcohol after com-
pletion of the diagnostic and invasive procedures, 
and after final qualification for MTH. 
Mild therapeutic hypothermia
Mild therapeutic hypothermia will be performed and 
monitored in a Cardiac Intensive Care Unit. The state 
of MTH is defined as body core temperature below 
34°C, with a target temperature of 33°C. To reach the 
target temperature and maintain it over the subsequent 
24 hours, methods of external and intravascular cooling 
118
Medical research journal 2016, vol. 1, no. 4
www.journals.viamedica.pl/medical_research_journal
Table 2. Exclusion criteria
EXCLUSION CRITERIA
Study group Control group
Overt or suspected pregnancy
Known serious infection/sepsis before OHCA
Known bleeding diathesis
Confirmed or suspected internal bleeding 
Confirmed or suspected acute stroke
Confirmed or suspected cerebral injury
Known serious neurological dysfunction (CPC ≤ 4) before OHCA
Known serious disease with survival prognosis ≤ 180 days
Haemodynamic instability with systolic blood pressure < 65 mm Hg 
despite treatment
Contraindications to ticagrelor
Administration of glycoprotein IIb/IIIa receptor inhibitor
Resuscitation duration < 5 min
Time delay from ROSC to MTH induction > 240 minutes
Overt or suspected pregnancy
Known serious infection/sepsis before OHCA
Known bleeding diathesis
Confirmed or suspected internal bleeding 
Confirmed or suspected acute stroke
Confirmed or suspected cerebral injury
Known serious neurological dysfunction (CPC ≤ 4) 
before OHCA
Known serious disease with survival prognosis  
≤ 180 days
Haemodynamic instability with systolic blood pressure  
< 65 mm Hg despite treatment
Contraindications to ticagrelor
Administration of glycoprotein IIb/IIIa receptor inhibitor
OHCA — out-of-hospital cardiac arrest; CPC — cerebral performance categories; MTH — mild therapeutic hypothermia
will be used. Immediately after PCI an MTH-dedicated 
catheter will be placed in the inferior vena cava through the 
femoral vein under fluoroscopic guidance in the cath lab.
Besides quick arrival at the target temperature 
and its successful maintenance, properly conducted 
hypothermia is also characterised by: bradycardia of 
40–50 bpm, urine output of > 1 mL/kg body weight/hour, 
and lack of shivers.
The treatment is focused on achieving the designat-
ed haemodynamic and biochemical goals. According 
to the 2008 International Liaison Committee Recom-
mendations, they include [10]:
 — body core temperature in the range of 33.0 ± 0.2°C;
 — mean arterial blood pressure of 65–95 mm Hg;
 — central venous pressure of 8–12 mm H2O;
 — blood saturation of 92–96% (90–94% for COPD 
patients);
 — diuresis > 1 mL/kg body weight/h; 
 — temperature-corrected normoxaemia in arterial 
blood sample;
 — temperature-corrected normocapnia in arterial 
blood sample;
 — potassium, calcium, and phosphorus concentra-
tions within normal ranges;
 — lactate concentration < 2 mmol/L;
 — blood glucose concentration of 110–170 mg/dL;
 — maintenance of 24-hour fluid balance (with con-
trolled administration of colloid/crystalloid fluids) at 
approx. –300 to 0 mL;
 — central venous oxygen saturation > 70%.
Pharmacodynamics of ticagrelor
Blood samples will be drawn at predefined time 
points: before administration of a 180-mg loading dose 
of ticagrelor, then after: 30 minutes, and 1, 2, 3, 4, 6, 
12, and 24 hours.
For assessment of ticagrelor pharmacodynamics 
four different methods will be used:
 — light transmission aggregometry (LTA — 490-4D 
Chronolog) — ADP-induced aggregation;
 — impedance aggregometry using semi-automatic 
analyser Multiplate — ADP-induced aggregation;
 — automatic VerifyNow — P2Y12 assay — ADP-in-
duced aggregation;
 — platelet vasodilator-stimulated phosphoprotein (VASP) 
assay using flow cytometer FASCalibur (the most spe-
cific method for the quantification of the pharmacody-
namic effects of platelet P2Y12 receptor inhibitors), an-
alysed parameter: platelet reactivity index (PRI/VASP).
Pharmacokinetics of ticagrelor and its 
active metabolite (AR-C124910XX)
Blood plasma concentrations of ticagrelor and 
AR-C124910XX will be evaluated at the same time points 
as pharmacodynamics, using liquid chromatography 
mass spectrometry.
Basic study information
 — Single-centre, prospective, observational study;
 — comparing two groups of patients:
•	 OHCA patients after resuscitation undergoing 
MTH therapy, treated with primary PCI and 
ticagrelor due to STEMI,
•	 patients with STEMI treated with pPCI and tica-
grelor;
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 — duration of observation: 24 hours;
 — primary endpoint: ADP-induced platelet aggregation 
assessed with impedance aggregometry Multiplate 
analyser at: 30 minutes, and 1, 2, 3, 4, 6, 12, and 
24 hours after administration of a 180-mg loading 
dose of ticagrelor;
 — secondary endpoints:
•	 ADP-induced platelet aggregation assessed with 
light transmission aggregometry (LTA) at: 30 min-
utes, and 1, 2, 3, 4, 6, 12, and 24 hours after ad-
ministration of a 180-mg loading dose of ticagrelor.
•	 platelet reactivity index (PRI/VASP) assessed 
with flow cytometer at: 30 minutes, and 1, 2, 
3, 4, 6, 12, and 24 hours after administration of 
a 180-mg loading dose of ticagrelor,
•	 ADP induced platelet aggregation assessed with 
VerifyNow analyzer at: 30 minutes, and 1, 2, 3, 
4, 6, 12, and 24 hours after administration of 
a 180-mg loading dose of ticagrelor,
•	 area under the curve of ticagrelor concentration 
and its metabolite AR-C124910XX levels during 
follow-up (AUCO-t),
•	 maximum concentration of ticagrelor (Cmax) and 
its metabolite AR-C124910XX,
•	 time to reach Cmax of ticagrelor and its metab-
olite AR-C124910XX,
•	 ticagrelor serum concentration at: 30 minutes, 
and 1, 2, 3, 4, 6, 12, and 24 hours after admin-
istration of a 180-mg loading dose of ticagrelor,
•	 AR-C124910XX serum concentration at: 30 min-
utes, and 1, 2, 3, 4, 6, 12, and 24 hours after admin-
istration of a 180-mg loading dose of ticagrelor;
 — clinical endpoint: stent thrombosis within 24 hours 
of study;
 — safety endpoint: bleeding by the BARC criteria, 
bradyarrhythmias.
Characteristics of the final result
Understanding the mechanisms behind the im-
pact of MTH on the efficacy of platelet inhibition with 
P2Y12 inhibitors is pivotal to reduce the risk of throm-
botic complications. The study is expected to provide 
information allowing us to improve the safety of MTH 
in STEMI patients with OHCA, treated with pPCI, and 
receiving ticagrelor. 
This study has been developed as part of the “Dia-
mond Grant” project financed by the Ministry of Science 
and Higher Education of the Republic of Poland from 
research funds for the years 2015–2018.
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